Researchers have discovered the genetic fingerprint that assists physicians to differentiate the aggressive development of prostate cancer in the men who presents with curable localized prostate cancer.
Dr. Robert Bristow who is a clinician-scientist in Princess Margaret Cancer Centre carried out an extensive research on 500 Canadian men who presented with localized prostate cancer. Dr. Robert elaborated, “We focused on the DNA or genetics of the men with localized prostate cancer to understand the genetic fingerprint which was different from man to man. To achieve the goal, we use specialized state-of-art DNA sequencing techniques to focus on the genetics of prostate cancer”.
These genetic fingerprints predict the patients who might have an early metastasis versus those patients who have only a localized prostate cancer. This information will further help doctors to choose an appropriate method of treatment for patients by identifying their category which will eventually increase the curability of cancer. “We are excited because this is a new genetic signature in prostate cancer that gives us information about which patients may have the hidden spread of the disease versus those patients that do not,” said Dr. Robert in respect of the use of the information.
Researchers developed this genetic information by analyzing different characteristics of the prostate tumor instead of anchoring only one. This helps to offer initial targeted therapy to the patients who are prone to spread the disease and treat them more effectively before it becomes incurable.
Dr. Robert shared his aim, “We want to translate this research finding into a molecular diagnostic tool that can be used in the clinic.” According to his comment, it would take another two or three years of research to be sure the results are correct before it can be introduced at the clinical level.
Movember funded this research through Prostate Cancer Canada, the Ontario Institute for Cancer Research, the Canadian Institute for Health Research, the Canadian Cancer Society, and The Princess Margaret Cancer Foundation.